Randomized Comparative Trial of a Ward Discussion Group

West, EricD.; Jackson, Archi; Physentides, A; Seenivasagan, S; Jezard, P; Nicholson, Alex; Ram, R; Knight, Helen

doi:10.1192/bjp.141.1.76

Cited by 6 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the Hawthorne effect (i.e., "the positive effect observed in patients from the attention received in a study" 29 ) was taken into account; therefore, baseline number of episodes was calculated as the sum of the episodes during the 15 days previous to inclusion and the 15 days after inclusion.…”

Section: Discussionmentioning

confidence: 99%

Efficiency of Venlafaxine in Patients With Psychogenic Nonepileptic Seizures and Anxiety and/or Depressive Disorders

Pintor

Baillès²,

Matrai³

et al. 2010

JNP

View full text Add to dashboard Cite

An open-label, experimental, prospective 5-month follow-up study was performed with 19 patients with psychogenic nonepileptic seizures and anxiety disorder and/or depression who were treated with venlafaxine. The authors held monthly visits and evaluated changes in baseline Hamilton Depression Rating Scale scores, Hamilton Anxiety Rating Scale scores, and the number of psychogenic nonepileptic seizures. HAM-D scores, HAM-A scores, and the number of nonepileptic seizures showed a statistically significant decrease which was maintained over the study period. Based on this study, the authors conclude that venlafaxine may help reduce nonepileptic seizures in patients with additional anxious and/or depressive symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficiency of Venlafaxine in Patients With Psychogenic Nonepileptic Seizures and Anxiety and/or Depressive Disorders

Pintor

Baillès²,

Matrai³

et al. 2010

JNP

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…The Hawthorne effect (the positive effect observed in patients from the attention received in a study) may come into play with trials enrolling these patients. 19 We collected the retrospective 2 week seizure count at enrollment, and to address the potential Hawthorne effect, compared it to the frequency of events in the 2 week treatment free baseline period (8.4 and 7.5 NES). Monitoring patients for seizures and symptoms prior to receiving the intervention may be essential to look for changes, either positive or negative, from enrollment to initiation of therapy.…”

mentioning

confidence: 99%

Methodological Issues in Conducting Treatment Trials for Psychological Nonepileptic Seizures

LaFrance

Blum²,

Miller³

et al. 2007

JNP

View full text Add to dashboard Cite

A randomized, placebo-controlled trial has yet to be completed in patients with psychological nonepileptic seizures (NES). Treatment publications for NES are limited to class III trials and class IV reports. Little is written on the methodology of treatment trials in NES. The authors describe the procedures and limitations of such a trial to inform future NES treatment trials, based on their prospective, open-label pharmacological, feasibility trial. The authors review the recruitment, enrollment, completion of surveys, compliance, and follow-up of patients with NES. The majority of patients who enrolled, readily completed surveys and took the medication during the trial. Twelve patients were screened, eight enrolled, and six completed the trial. The authors discuss the use of outcomes and the various symptoms scales in the trial. A comprehensive neuropsychiatric initial assessment and assessing cognitive, emotional, behavioral, and psychosocial measures are important for monitoring the outcomes in NES treatment RCTs.Patients with psychological nonepileptic seizures are often severely disabled, refractory to treatment, and frequently are encountered in neurology, psychiatry, and emergency departments. Nonepileptic seizures (NES), also referred to as pseudoseizures, are paroxysmal behaviors which have psychological comorbidities and are unresponsive to treatment with antiepileptic drugs. The phenomenology of NES is well delineated, including a preliminary understanding of risk factors and prognostic features. 1 A number of studies exist on the diagnosis of NES, ictal semiology, comorbid psychiatric diagnoses, and neurological and neuropsychological characteristics of patients with NES. To date, no double-blinded, randomized, placebo-controlled trial has been completed for patients diagnosed with NES.Given the paucity of systematic treatment trials for NES, much less is known about treatments of NES. A review of the literature reveals that only class III and IV studies are available, and no effective treatments have been developed. 2 Patients with NES present unique challenges, given the overlap of neurological and psychiatric presentations. The number of papers in journals addressing clinical trial methodology in individual neurological or psychiatric disorders is limited. [3][4][5] The few present do not adequately address when combined neuropsychiatric issues are present in a single trial. The purpose of this report is to describe Address correspondence to Dr. LaFrance, Rhode Island Hospital, 593 Eddy Street, Potter 3, Neuropsychiatry, Providence, RI 02903; William_LaFrance_Jr@Brown.edu (e-mail). Portions of this paper were presented at a poster session at the NINDS/American Neurological Association Symposium, in Toronto, Ontario, Canada, October 2, 2004. Patients with NES often have comorbid psychiatric conditions, such as major depressive disorder and anxiety disorders, including PTSD, or symptoms of depression, anxiety, and impulsivity seen in characterological disorders. 6 Mood, anxiety, and impulsi...

show abstract

Electroconvulsive therapy for schizophrenia

Tharyan

2002

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Randomized Comparative Trial of a Ward Discussion Group

Cited by 6 publications

References 2 publications

Efficiency of Venlafaxine in Patients With Psychogenic Nonepileptic Seizures and Anxiety and/or Depressive Disorders

Efficiency of Venlafaxine in Patients With Psychogenic Nonepileptic Seizures and Anxiety and/or Depressive Disorders

Methodological Issues in Conducting Treatment Trials for Psychological Nonepileptic Seizures

Electroconvulsive therapy for schizophrenia

Contact Info

Product

Resources

About